Literature DB >> 33614584

Clinical and Demographic Characteristics of Patients With a New Diagnosis of Carriage or Clinical Infection With Carbapenemase-Producing Enterobacterales: A Retrospective Study.

Assaf Adar1, Hiba Zayyad1,2, Maya Azrad3, Kozita Libai2, Ilana Aharon2, Orna Nitzan1,2, Avi Peretz1,3.   

Abstract

Background: To examine the clinical, demographic, and microbiologic characteristics of new rectal carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) carriers vs. those with a clinical infection, hospitalized at Padeh-Poriya Medical Center between 2014 and 2017 and to examine the susceptibility profiles of isolates from clinical infections.
Methods: In this retrospective, chart analysis, demographic and clinical data were collected from medical charts of 175 adult patients with either new- onset carbapenemase-producing Enterobacterales (CPE) carriage or clinical CPE infection. Collected data included age, ethnic group, place of residence, hospitalizations in the past 90 days, and 30-day mortality. Microbiological analyses considered bacterial genus, molecular resistance mechanism and antibiotic susceptibility.
Results: A significantly higher percentage (42.4%) of CPE carriers were long-term care facility residents, and had been recently hospitalized (56.3%), as compared to patients with clinical CPE infection (29.2 and 45.9%, respectively). Additionally, we noted a high (58.3%) acquision of CPE in our hospital. The most common bacterial isolate was K. pneumoniae and the most common resistance mechanism was Klebsiella pneumoniae (K. pneumoniae) carbapenemases (KPC). High susceptibility rates to amikacin and chloramphenicol were also noted. Conclusions: This study reaffirmed the importance of CPE screening and infection control measures. The observed antibiotic susceptibility profile suggests amikacin and chloramphenicol as potential treatments for CPE infection.
Copyright © 2021 Adar, Zayyad, Azrad, Libai, Aharon, Nitzan and Peretz.

Entities:  

Keywords:  Israel; antibiotic resistance; carbapenem-resistant Enterobacterales; carbapenemase-producing Enterobacterales; carrier

Year:  2021        PMID: 33614584      PMCID: PMC7892593          DOI: 10.3389/fpubh.2021.616793

Source DB:  PubMed          Journal:  Front Public Health        ISSN: 2296-2565


  27 in total

Review 1.  An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2013-12-04       Impact factor: 9.079

Review 2.  The global epidemiology of carbapenemase-producing Enterobacteriaceae.

Authors:  David van Duin; Yohei Doi
Journal:  Virulence       Date:  2016-08-11       Impact factor: 5.882

3.  Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Authors:  Pranita D Tamma; Katherine E Goodman; Anthony D Harris; Tsigereda Tekle; Ava Roberts; Abimbola Taiwo; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2016-11-09       Impact factor: 9.079

4.  Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.

Authors:  Nusaibah Abdul Rahim; Soon-Ee Cheah; Matthew D Johnson; Heidi Yu; Hanna E Sidjabat; John Boyce; Mark S Butler; Matthew A Cooper; Jing Fu; David L Paterson; Roger L Nation; Phillip J Bergen; Tony Velkov; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-05-28       Impact factor: 5.790

Review 5.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.

Authors:  Latania K Logan; Robert A Weinstein
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

6.  Increased Mortality Among Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Carriers Who Developed Clinical Isolates of Another Genotype.

Authors:  Wen Kai Chen; Yong Yang; Ban Hock Tan
Journal:  Open Forum Infect Dis       Date:  2019-02-01       Impact factor: 3.835

Review 7.  Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.

Authors:  Dmitriy M Martirosov; Thomas P Lodise
Journal:  Diagn Microbiol Infect Dis       Date:  2015-10-14       Impact factor: 2.803

Review 8.  Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae.

Authors:  Liangfei Xu; Xiaoxi Sun; Xiaoling Ma
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-03-29       Impact factor: 3.944

Review 9.  Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options.

Authors:  Chau-Chyun Sheu; Ya-Ting Chang; Shang-Yi Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2019-01-30       Impact factor: 5.640

10.  Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria.

Authors:  Atul Garg; Jaya Garg; Sachin Kumar; Amitabh Bhattacharya; Saurabh Agarwal; G C Upadhyay
Journal:  Indian J Med Res       Date:  2019-02       Impact factor: 2.375

View more
  1 in total

Review 1.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.